Randomized Trial of Mycophenolate Mofetil Versus Enteric-Coated Mycophenolate Sodium in Primary Renal Transplantation With Tacrolimus and Steroid Avoidance: Four-Year Analysis

Abstract

This is the first long-term, randomized trial comparing enteric-coated mycophenolate sodium versus mycophenolate mofetil along with reduced maintenance tacrolimus dosing and steroid avoidance, which resulted in similarly low-BPAR rates, acceptably high renal function at 48 months, and an equivalent side effect profile.

Treatment of Mucous Membrane Pemphigoid With Mycophenolate Mofetil

“…14 Current literature has debated whether MMF or MPS offers a better side effect profile. 27,28 All patients in this study were initially placed on MMF. One patient was switched to MPS secondary to hypokalemia, myalgia, insomnia, and anorexia.…”

Single-centre study of 628 adult, primary kidney transplant recipients showing no unfavourable effect of new-onset diabetes after transplant

“…We were therefore interested in determining the prognostic impact of NODAT among patients receiving transplants at our centre. To maximise statistical power, we combined data for all study participants in four randomised immunosuppression trials of adult, primary kidney transplantation performed at our centre since May 2000 [22][23][24][25][26][27][28][29][30][31][32], yielding a prospectively followed cohort of 628 patients. Results from this observational study are presented here.…”

“…: NCT00681213, NCT00685061, NCT00681343, NCT00533624 and NCT01172418; note: two distinct registration numbers exist in the second trial, because separate randomisations of deceased donor and living donor recipients were performed). Results of these randomised trials have been reported previously (details omitted here) [22][23][24][25][26][27][28][29][30][31][32].…”

Current Immunosuppression in Abdominal Organ Transplantation

“…This may help alleviate some of the gastrointestinal side effects of mycophenolate mofetil. There is no significant difference in rejection and side effects in large randomized trial of mycophenolate mofetil versus mycophenolate sodium (Ciancio et al, 2011). The ability of mycophenolic acid to facilitate sparing of other immunosuppressive agents, particularly cyclosporine and its related nephrotoxicity, is promising.…”